Drug Development

It is currently estimated by the Alzheimer’s foundation of America that 5.1 million Americans, may have Alzheimer’s disease. Current research from the National Institute on Aging indicates that the prevalence of Alzheimer’s disease doubles every five years beyond age 65. As our population ages, the disease impacts a greater percentage of Americans. The number of people age 65 and older will more than double between 2010 and 2050 to 88.5 million or 20 percent of the population; likewise, those 85 and older will rise three-fold, to 19 million, according to the U.S. Census Bureau. It is estimated that about a half million Americans younger than age 65 have some form of dementia, including Alzheimer’s disease referred to as early onset. It is estimated that one to four family members act as caregivers for everyone with Alzheimer’s disease. There are many prescription drugs available, including extended release products. In the Ayurvedic as well as other ancient systems of medicine, many botanicals have been used for dementia, as well Alzheimer’s and other neuro-pathologies. Our aim is to develop a unique potent formulation using these natural compounds in a preventative capacity, with novel drug delivery systems. Our company is based in Tampa, and is affiliated with the Tampa Bay Technology incubator, as well as the University of South Florida.